When combined with an OV, however, erastin enhanced the number of activated DCs and the activity of tumor-infiltrating T lymphocytes (based on increased IFN-γ+CD8+ and PD-1+CD8+ T cells), leading to improved therapy in tumor models in mice [301]. Here, CD8A is linked to neoplasm.